|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Longo D, Fauci A, Kasper D, Hauser S,
Jameson J and Loscalzo J: Harrison's Principles of Internal
Medicine. 18th. McGraw-Hill Professional; New York, NY: 2011
|
|
3
|
Dacic S, Flanagan M, Cieply K, Ramalingam
S, Luketich J, Belani C and Yousem SA: Significance of EGFR protein
expression and gene amplification in non-small cell lung carcinoma.
Am J Clin Pathol. 125:860–865. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wrann MM and Fox CF: Identification of
epidermal growth factor receptors in a hyperproducing human
epidermoid carcinoma cell line. J Biol Chem. 254:8083–8086.
1979.PubMed/NCBI
|
|
5
|
Paez JG, Jänne PA, Lee JC, Tracy S,
Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et
al: EGFR mutations in lung cancer: Correlation with clinical
response to gefitinib therapy. Science. 304:1497–1500. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Prewett M, Rockwell P, Rockwell RF,
Giorgio NA, Mendelsohn J, Scher HI and Goldstein NI: The biologic
effects of C225, a chimeric monoclonal antibody to the EGFR, on
human prostate carcinoma. J Immunother Emphasis Tumor Immunol.
19:419–427. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kris MG, Natale RB, Herbst RS, Lynch TJ
Jr, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H,
Sandler A, et al: Efficacy of gefitinib, an inhibitor of the
epidermal growth factor receptor tyrosine kinase, in symptomatic
patients with non-small cell lung cancer: A randomized trial. JAMA.
290:2149–2158. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shigematsu H and Gazdar AF: Somatic
mutations of epidermal growth factor receptor signaling pathway in
lung cancers. Int J Cancer. 118:257–262. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lynch TJ, Bell DW, Sordella R,
Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat
SM, Supko JG, Haluska FG, et al: Activating mutations in the
epidermal growth factor receptor underlying responsiveness of
non-small-cell lung cancer to gefitinib. N Engl J Med.
350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Johnson BE and Jänne PA: Epidermal growth
factor receptor mutations in patients with non-small cell lung
cancer. Cancer Res. 65:7525–7529. 2005.PubMed/NCBI
|
|
11
|
Yun CH, Mengwasser KE, Toms AV, Woo MS,
Greulich H, Wong KK, Meyerson M and Eck MJ: The T790M mutation in
EGFR kinase causes drug resistance by increasing the affinity for
ATP. Proc Natl Acad Sci USA. 105:pp. 2070–2075. 2008; View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pao W, Miller VA, Politi KA, Riely GJ,
Somwar R, Zakowski MF, Kris MG and Varmus H: Acquired resistance of
lung adenocarcinomas to gefitinib or erlotinib is associated with a
second mutation in the EGFR kinase domain. PLoS Med. 2:e732005.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kobayashi S, Boggon TJ, Dayaram T, Jänne
PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG and Halmos
B: EGFR mutation and resistance of non-small-cell lung cancer to
gefitinib. N Engl J Med. 352:786–792. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kwak EL, Sordella R, Bell DW,
Godin-Heymann N, Okimoto RA, Brannigan BW, Harris PL, Driscoll DR,
Fidias P, Lynch TJ, et al: Irreversible inhibitors of the EGF
receptor may circumvent acquired resistance to gefitinib. Proc Natl
Acad Sci USA. 102:pp. 7665–7670. 2005; View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chikan N, Bukhari S, Shabir N, Amin A,
Shafi S, Qadri RA and Patel TN: Atomic insight into the altered
O6-Methylguanine-DNA methyltransferase protein architecture in
gastric cancer. PLoS One. 10:e01277412015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bukhari S, Mokhdomi TA, Chikan NA, Amin A,
Qazi H, Wani SH, Wafai AH, Tyub S, Mustafa F, Mir MS, et al:
Affinity proteomics led identification of vimentin as a potential
biomarker in colon cancers: Insights from serological screening and
computational modelling. Mol Biosyst. 11:159–169. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang X, Gureasko J, Shen K, Cole PA and
Kuriyan J: An allosteric mechanism for activation of the kinase
domain of epidermal growth factor receptor. Cell. 125:1137–1149.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Guex N and Peitsch MC: SWISS-MODEL and the
Swiss-Pdb Viewer: An environment for comparative protein modeling.
Electrophoresis. 18:2714–2723. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hess B, Kutzner C, van der Spoel D and
Lindahl E: GROMACS 4: Algorithms for highly efficient,
load-balanced, and scalable molecular simulation. J Chem Theory
Comput. 4:435–447. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Schuler LD, Daura X and Van Gunsteren WF:
An improved GROMOS96 force field for aliphatic hydrocarbons in the
condensed phase. J Comput Chem. 22:1205–1218. 2001. View Article : Google Scholar
|
|
21
|
Mark P and Nilsson L: Structure and
dynamics of the TIP3P, SPC, and SPC/E water models at 298K. J Phy
Chem. 105:9954–9960. 2001. View Article : Google Scholar
|
|
22
|
Berendsen HJC, Postma JPM, van Gunsteren
WF, DiNola A and Haak JR: Molecular dynamics with coupling to an
external bath. J Chem phys. 81:36841984. View Article : Google Scholar
|
|
23
|
DeLano WL: The PyMOL molecular graphics
system. 2002, http://www.pymol.org/May 30–2017
|
|
24
|
Humphrey W, Dalke A and Schulten K: VMD:
Visual molecular dynamics. J Mol Graph. 14:33–38, 27-28. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Turner PJ: XMGRACE, Version 5.1.19. Center
for Coastal and Land-Margin Research. Oregon Graduate Institute of
Science and Technology; Beaverton, OR: 2005
|
|
26
|
Zhao FL, Yang GH, Xiang S, Gao DD and Zeng
C: In silico analysis of the effect of mutation on epidermal growth
factor receptor in non-small-cell lung carcinoma: From mutational
analysis to drug designing. J Biomol Struct Dyn. 35:427–434. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Doss GP, Rajith B, Chakraborty C,
NagaSundaram N, Ali SK and Zhu H: Structural signature of the
G719S-T790M double mutation in the EGFR kinase domain and its
response to inhibitors. Sci Rep. 4:58682014.PubMed/NCBI
|
